Appendix BSearch Strategy

Publication Details

MEDLINE® (via PubMed) 1/10/12

Key Question 1

“Disease-Free Survival”[Mesh] OR “progression free survival” OR “progression-free survival” OR “time to progression”

AND

((“Quality of Life”[Mesh]) OR ( “Depression”[Mesh] OR “Depressive Disorder”[Mesh] )) OR “Anxiety”[Mesh] OR “clinical benefit” OR “clinical benefits” OR “quality of life” OR “patient-reported outcomes” OR depression OR anxiety OR “psychological”

AND

“Neoplasms”[Mesh] OR cancer OR neoplasms OR carcinoma

AND

(“progression-free” OR “progression free”) Field: Title/Abstract

AND

Limits: Humans, English, Publication Date from 1999 to 2012

We made 2 sets – one with publication types letter, editorial, comment, OR review – the second was the rest of the articles in the set.

Key Question 2 includes the above search AND

Additional drug specific searches -

(“bevacizumab” [Supplementary Concept] OR Bevacizumab OR avastin) AND (“Breast Neoplasms”[Mesh] OR (breast AND (cancer OR cancers OR neoplasms OR carcinoma*)) AND (“progression-free survival” OR “time to progression”)

(“ixabepilone” [Supplementary Concept] OR ixabepilone OR ixempra) AND (“Breast Neoplasms”[Mesh] OR (breast AND (cancer OR cancers OR neoplasms OR carcinoma*)) AND (“progression-free survival” OR “time to progression”)

(“lapatinib” [Supplementary Concept] OR lapatinib OR Tykerb) AND (“Breast Neoplasms”[Mesh] OR (breast AND (cancer OR cancers OR neoplasms OR carcinoma*)) AND (“progression-free survival” OR “time to progression”)

(“bevacizumab” [Supplementary Concept] OR Bevacizumab OR avastin) AND (“Colorectal Neoplasms”[Mesh] OR ((colon OR colorectal) AND (cancer OR cancers OR neoplasms OR carcinoma*))) AND (“progression-free survival” OR “time to progression”)

(“panitumumab” [Supplementary Concept] OR panitumumab OR vectibix) AND (“Colorectal Neoplasms”[Mesh] OR ((colon OR colorectal) AND (cancer OR cancers OR neoplasms OR carcinoma*))) AND (“progression-free survival” OR “time to progression”)

(“Doxorubicin”[Mesh] OR doxorubicin OR doxil) AND (“Ovarian Neoplasms”[Mesh] OR ((ovary OR ovarian) AND (cancer OR cancers OR neoplasms OR carcinoma*))) AND (“progression-free survival” OR “time to progression”)

(“gemcitabine” [Supplementary Concept] OR gemcitabine OR gemzar) AND (“Ovarian Neoplasms”[Mesh] OR ((ovary OR ovarian) AND (cancer OR cancers OR neoplasms OR carcinoma*))) AND (“progression-free survival” OR “time to progression”)

(“trabectedin” [Supplementary Concept] OR trabectedin OR yondelis) AND (“Ovarian Neoplasms”[Mesh] OR ((ovary OR ovarian) AND (cancer OR cancers OR neoplasms OR carcinoma*))) AND (“progression-free survival” OR “time to progression”)

(“sorafenib” [Supplementary Concept] OR sorafenib OR nexavar) AND (“Carcinoma, Renal Cell”[Mesh] OR “renal cell carcinoma”) AND (“progression-free survival” OR “time to progression”)

(“pazopanib” [Supplementary Concept] OR pazopanib OR votrient) AND (“Carcinoma, Renal Cell”[Mesh] OR “renal cell carcinoma”) AND (“progression-free survival” OR “time to progression”)

(“sunitinib” [Supplementary Concept] OR sunitinib OR sutent) AND (“Carcinoma, Renal Cell”[Mesh] OR “renal cell carcinoma”) AND (“progression-free survival” OR “time to progression”)

(“erlotinib” [Supplementary Concept] OR erlotinib OR tarceva) AND (“Carcinoma, Non-Small-Cell Lung”[Mesh] OR (“non-small cell lung” AND (cancer OR cancers OR neoplasms OR carcinoma))) AND (“progression-free survival” OR “time to progression”)

(“docetaxel”[Mesh] OR doxetaxel OR taxotere) AND (“Head and Neck Neoplasms”[Mesh] OR ((“head and neck”) AND (cancer OR cancers OR carcinoma* OR neoplasms))) AND (“progression-free survival” OR “time to progression”)

The EMBASE search was

‘progression-free survival’/exp OR ‘time to progression’ in abstract or title

AND

‘clinical benefit’ OR ‘clinical benefits’ OR ‘quality of life’/exp OR ‘patient-reported outcomes’ OR ‘depression’/exp OR ‘anxiety’/exp OR ‘psychological’

AND

‘cancer’/exp OR ‘neoplasms'/exp OR ‘carcinoma’/exp

AND

Human/English/1999–2012

NOT MEDLINE

MEDLINE 12/26/2011 = 293

For KQ1: ‘progression-free survival’/OR ‘PFS’

AND

‘clinical benefit’ OR ‘quality of life’ OR ‘patient-reported outcomes’ OR ‘depression’ OR ‘anxiety’ OR ‘psychological’

AND ‘cancer’

For KQ2: above AND each of the convenience drugs added individually

Limited to human/English/post 1999 (KQ1) or 2004 (KQ2)

above search limited to ‘randomized’ = 82

Sets – N=1505

From Medline = 82

KQ1_EMBASE = 426

KQ1_PubMed_EditComm=232 (these are the editorials, comments, letters and reviews from PubMed)

KQ1_PubMed_nonindexed=105 (these are the PubMed nonindexed that search obtained but that fell out when the English, Human and 1999–2012 limits were added)

KQ1_PubMed=655 (these are the PubMed results for the search strategy that we discussed minus the editorials, comments, letters and reviews above)

KQ2_PubMed=5 (these are the drug specific search results that were not already in the database – there were no drug specific search unique records in EMBASE).